XXXX . Clinical practice guidelines in oncology.

@entity1 @entity308 @entity417 @entity5 @entity1295 @entity1307 @entity158 @entity299 @entity25
These guidelines propose a treatment algorithm in which @entity1 are evaluated regularly for @entity1295 using a brief screening instrument, and are treated as indicated by their @entity1295 level. The algorithm's goal is to identify and treat all @entity1 with @entity1295 that causes distress or interferes with their daily activities or functioning. Management of @entity1295 begins with primary oncology team members who perform the initial screening and either provide basic education and counseling or expand the initial screening to a more focused evaluation for moderate or higher levels of @entity1295 . At this point the @entity1 is assessed for current disease and treatment status, a review of body systems, and an in-depth @entity1295 evaluation. In addition, the @entity1 is assessed for the presence of seven treatable factors known to contribute to @entity1295 : @entity158 , @entity25 , @entity417 , alterations in nutrition, deconditioning, and comorbidities. If any of these conditions are present, they should be treated according to practice guidelines, with referral to other care professionals as appropriate, and the @entity1 's @entity1295 should be reevaluated regularly. If none of the seven factors are present or the @entity1295 is unresolved, selection of appropriate @entity1295 management and treatment strategies is considered within the context of the @entity1 's clinical status: receiving active cancer treatment, receiving disease-free long-term follow-up, or receiving care at the end of life. Management of @entity1295 is cause-specific when conditions known to cause @entity1295 can be identified and treated. When specific causes, such as infection, fluid and electrolyte imbalances, or @entity299 , cannot be identified and corrected, nonpharmacologic and pharmacologic treatment of the @entity1295 should be considered. Nonpharmacologic interventions may include a moderate exercise program to improve functional capacity and activity tolerance, psychosocial programs to manage stress and increase support, restorative therapies to decrease cognitive alterations and improve mood state, and nutritional and sleep interventions for @entity1 with disturbances in eating or sleeping. Pharmacologic therapy may include drugs, such as antidepressants for @entity308 or @entity1307 for @entity417 . A few clinical reports of the use of psychostimulants suggest the need for further research on these agents as potential treatment modalities in managing @entity1295 . Effective management of @entity5 involves an informed and supportive oncology care team that assesses @entity1 ' @entity1295 levels regularly and systematically, educates and counsels @entity1 regarding strategies for coping with @entity1295 , and uses institutional @entity1295 management experts for referral of @entity1 with unresolved @entity1295 .
